Literature DB >> 8932341

Fibronectin promotes the proliferation of cytotoxic T lymphocytes generated from cancer patients.

S Mizobata1, H Tanimura, H Yamaue, M Tani, T Tsunoda, M Iwahashi, K Noguchi, N Nishimoto, T Hotta, K Arii.   

Abstract

We studied whether fibronectin (FN) enhances the activity of autologous tumour-reactive cytotoxic T lymphocytes (CTLs) generated from cancer patients. The proliferation of CTLs stimulated by immobilised anti-CD3 monoclonal antibody and interleukin 2 (IL-2) was enhanced three or four times by immobilised FN. whereas soluble FN did not alter the DNA synthesis of CTLs. Moreover, the cytotoxic activity of CTLs was augmented by FN stimulation against autologous tumour cells [4 h 51Cr release assay: FN(+) 16.7 +/- 4.7% vs FN (-) 11.8 +/- 3.1%; 16 h 51Cr release assay: FN(+) 24.8 +/- 4.7% vs FN (-) 16.5 +/- 5.7%, P<0.05]. The major cell surface phenotype of CTLs with FN was CD3+, CD4+ and CD25+ in 6 weeks' culture. Cytotoxicity against autologous tumour cells was inhibited by anti-HLA class I monoclonal antibody (MAb). The autologous tumour-killing activity of CTLs was suppressed by the elimination of CD4+ cells. Moreover, the cytokine production of CTLs was augmented by FN stimulation. Especially, the production of IL-2, interferon gamma (IFN-gamma), and granulocyte macrophage colony-stimulating factor (GM-CSF) was significantly augmented by FN stimulation (P<0.05). Thus, CTLs generated by FN might have both killer and helper functions, since they could lyse autologous tumour cells and secrete various cytokines, including IL-2.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8932341      PMCID: PMC2074855          DOI: 10.1038/bjc.1996.595

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  30 in total

1.  Induction of activated natural killer cells from murine spleen cells primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK432.

Authors:  H Yamaue; M Katsumi; K Tabuse; Y Tabuse; K Kuribayashi; T Nishihara; K Saito
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  A new murine CD4+ T cell subset with an unrestricted cytokine profile.

Authors:  G S Firestein; W D Roeder; J A Laxer; K S Townsend; C T Weaver; J T Hom; J Linton; B E Torbett; A L Glasebrook
Journal:  J Immunol       Date:  1989-07-15       Impact factor: 5.422

3.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors:  S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

4.  Human cytotoxic T cell structures associated with expression of cytolysis. I. Analysis at the clonal cell level of the cytolysis-inhibiting effect of 7 monoclonal antibodies.

Authors:  B Malissen; N Rebai; A Liabeuf; C Mawas
Journal:  Eur J Immunol       Date:  1982-09       Impact factor: 5.532

5.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors:  S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

6.  Specific cytotoxicity of a long-term cultured T-cell clone on human autologous mammary cancer cells.

Authors:  T Sato; N Sato; S Takahashi; H Koshiba; K Kikuchi
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

7.  Role of interleukin-2 and interferon-gamma in induction of activated natural killer cells from mice primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK432.

Authors:  H Yamaue; H Tanimura; M Iwahashi; M Tani; T Tsunoda; K Tabuse; K Kuribayashi; K Saito
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

8.  Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex.

Authors:  T Matsuyama; A Yamada; J Kay; K M Yamada; S K Akiyama; S F Schlossman; C Morimoto
Journal:  J Exp Med       Date:  1989-10-01       Impact factor: 14.307

9.  Augmentation of human cytotoxic T lymphocytes against autologous tumor by a factor released from human monocytic leukemia cell line.

Authors:  N Maeda; S Hamasato; H Miyazawa; M Takata; H Yamamoto; S Fujimoto
Journal:  Jpn J Cancer Res       Date:  1989-06

10.  Chemosensitivity testing of fresh human gastric cancer with highly purified tumour cells using the MTT assay.

Authors:  H Yamaue; H Tanimura; K Noguchi; T Hotta; M Tani; T Tsunoda; M Iwahashi; M Tamai; S Iwakura
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.